Vivani Medical VANI Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net Income Loss by Business | ||||||
| Biopharm Division | -$6.01M-6.5% | -$6.2M-12.0% | -$5.9M-8.5% | -$6.4M-32.7% | -$5.65M-3.5% | |
| Neuromodulation Division | -$768K-9.7% | —— | -$700K-16.5% | -$800K-50.4% | -$700K-19.7% | |
| Other Nonoperating Income Expense by Business | ||||||
| Biopharm Division | -$209K+29.4% | $1.72M-23.5% | -$237K+22.5% | -$359K-0.8% | -$296K-26.5% | |
| Neuromodulation Division | $42K+2.4% | —— | $42K-4.5% | $41K-8.9% | $41K-10.9% | |
| Operating Expenses by Business | ||||||
| Biopharm Division | $6M0.0% | $6.2M— | $6.1M— | $6.7M— | $6M— | |
| Neuromodulation Division | $800K+33.3% | —— | $600K— | $700K— | $600K— | |
| Total Assets by Business | ||||||
| Biopharm Division | $41.9M+20.7% | $38.9M— | $24.6M— | $28.2M— | $34.7M— | |
| Neuromodulation Division | $500K-28.6% | —— | $400K— | $700K— | $700K— | |
| Other General And Administrative Expense by Business | ||||||
| Biopharm Division | $287K+77.2% | $222K-4.7% | $180K-28.3% | $220K+7.8% | $162K+29.6% | |
| Neuromodulation Division | $86K+75.5% | —— | $110K+134% | $107K+81.4% | $49K-65.0% | |
| Operating Lease Expense by Business | ||||||
| Biopharm Division | $1.13M+6.1% | $1.07M-1.2% | $1M-4.4% | $1.08M+16.1% | $1.06M+13.2% | |
| Neuromodulation Division | $30K-72.7% | —— | $54K-51.8% | $96K-12.7% | $110K+340% | |
| Labor And Related Expense by Business | ||||||
| Biopharm Division | $2.61M+5.5% | $2.7M+8.4% | $2.52M-2.6% | $2.59M+3.9% | $2.47M-0.7% | |
| Neuromodulation Division | $390K+76.5% | —— | $296K+9.6% | $298K+75.3% | $221K+85.7% | |
| Depreciation And Amortization by Business | ||||||
| Biopharm Division | $130K+31.3% | $112K+21.7% | $101K+2.0% | $98K+3.2% | $99K+7.6% | |
| Professional Services And Insurance Expense by Business | ||||||
| Biopharm Division | $1.06M-19.7% | $893K-22.5% | $1.2M+21.7% | $1.5M+42.0% | $1.32M-6.3% | |
| Neuromodulation Division | $220K-5.2% | —— | $172K+43.3% | $234K+67.1% | $232K+70.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Vivani Medical break its business down?
- Vivani Medical (VANI) reports net income loss by business across 3 parts — Biopharm Division, Neuromodulation Division and Neurostimulation Division. Each is extracted from the segment footnotes and tracked over time.
- Where does Vivani Medical's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Vivani Medical's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.